Enhanced pairing. Unlocking potential.

We are a proximity-based therapeutics company with expertise across bifunctional platforms, including PROTAC, tPRIME™, and PHICS™. Our platforms create chimeric small molecules that induce proximity between a target biomolecule of interest, e.g., a protein associated with disease, and an effector biomolecule, such as a ligase, a transcriptional regulator, or a kinase. Our proximity-induced approaches can selectively modulate otherwise “undruggable” target biomolecules to achieve a desired alteration of a target’s biologic function, which may be applied in a tissue-selective or cell compartment-selective manner depending on the platform employed. We are applying our deep chemistry and computational expertise across these platforms to advance a best-in-class pipeline of medicines for oncology, autoimmune and inflammatory diseases, and cardiometabolic diseases.

​

Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – Wendy Young, GV Advisor, Angela Koehler, MIT Associate Professor of Biological Engineering, Tony Hunter, Salk Institute Professor, Dan Nomura, UC Berkeley Professor of Chemical Biology and Molecular Therapeutics, and Eric Fischer, Independent Investigator Dana Farber Cancer Institute.